Search Results - "Bohwa Sohn"

Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial by Yim, Sun Young, Lee, Sung Hwan, Baek, Seung-Woo, Sohn, Bohwa, Jeong, Yun Seong, Kang, Sang-Hee, Park, Kena, Park, Hyewon, Lee, Sunyoung S, Kaseb, Ahmed O, Park, Young Nyun, Leem, Sun-Hee, Curran, Michael A, Kim, Ji Hoon, Lee, Ju-Seog

“…Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC)…”
Get full text

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial by Sun Young Yim, Sung Hwan Lee, Seung-woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-seog Lee

“…Background/Aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular…”
Get full text

OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial by Yim, Sun Young, Baek, Seung-Woo, Lee, Sung-Hwan, Sohn, BoHwa, Jeong, Yun Seong, Kang, Sang-Hee, Park, Kena, Park, Hyewon, Lee, Sunyoung, Kaseb, Ahmed, Kim, Ji Hoon, Chu, In-Sun, Lee, Ju-Seog

Get full text

Abstract 6395: Metabolic dysregulation as a determinant of prognosis and response to sorafenib in liver cancer by Park, Hyewon, Park, Sowon, Lee, Sung-Hwan, Jeong, Yun Seong, Sohn, Bohwa, Yim, Sun Young, Lee, Ju-Seog

“…Abstract Background & Aims: Elevated metabolic activity is a defining characteristic of liver cancer. Nevertheless, our understanding of the molecular…”
Get full text

Abstract LB090: Predictive genomic biomarkers for atezolizumab plus bevacizumab combination immunotherapy response in liver cancer: Insights from the IMbrave150 trial by Lee, Ju-Seog, Yim, Sun Young, Baek, Seung-Woo, Lee, Sung Hwan, Sohn, BoHwa, Jeong, Yun Seong, Kang, Sanghee, Park, Kena, Park, Hyewon, Lee, Sunyoung S., Kaseb, Ahmed O., Kim, Ji Hoon, Chu, In-Sun

“…Abstract Introduction: Combination immunotherapy regimens, exemplified by atezolizumab plus bevacizumab or sintilimab paired with a bevacizumab biosimilar…”
Get full text